How much does one month of evantumumab treatment cost?

Amivantamab (amivantamab) is a monoclonal antibody drug for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC). It exerts anti-tumor effects by targeting two receptors: EGFR and MET. The price of this drug varies by region, purchase channel, and health insurance coverage. In the domestic market, the original drug of evantuzumab has just been launched, so patients may face higher prices when purchasing it.

Currently, the original drug of evantuzumab is on the market in Hong Kong, China, and the monthly treatment cost is approximately 10,000 yuan. Since the drug is infused intravenously and usually requires a dosing cycle every two weeks, the cost of one month's treatment is approximately 20,000 yuan. For patients who need long-term use, this cost may put great pressure on family finances, especially when there is no medical insurance reimbursement or the medical insurance reimbursement ratio is low.

For domestic patients, although the drug is not yet fully popular in mainland China, it can also be purchased through channels in Hong Kong and other regions. Patients can choose to purchase original drugs at pharmacies in Hong Kong, or through cross-border e-commerce platforms or direct mail services from medical institutions. However, the total cost of the purchase may increase further due to additional costs such as import and export charges, shipping charges, etc. Patients should clearly understand the source and related procedures of drugs before purchasing to ensure the quality and legality of the drugs.

Generally speaking, evantumumab is relatively expensive, so patients need to consider their financial ability, treatment needs, and the effectiveness of the drug when using it. If the high cost of drugs becomes a burden to the patient, it is recommended to communicate with the doctor in advance to understand whether other treatment options are available. In addition, patients can also pay attention to whether the drug will be included in medical insurance or have other financial support programs in the future, thereby reducing the cost of treatment.

Reference materials:https://www.rybrevant.com/